{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T22:59:01Z","timestamp":1773269941812,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.ygyno.2017.05.037","type":"journal-article","created":{"date-parts":[[2017,6,11]],"date-time":"2017-06-11T03:01:03Z","timestamp":1497150063000},"page":"399-404","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment"],"prefix":"10.1016","volume":"146","author":[{"given":"Erica M.","family":"Bednar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly D.","family":"Oakley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte C.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine C.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark F.","family":"Munsell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon N.","family":"Westin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen H.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ygyno.2017.05.037_bb0005","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/cncr.21536","article-title":"BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases","volume":"104","author":"Pal","year":"2005","journal-title":"Cancer"},{"issue":"23","key":"10.1016\/j.ygyno.2017.05.037_bb0010","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/jnci\/djj465","article-title":"Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada","volume":"98","author":"Risch","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"issue":"21","key":"10.1016\/j.ygyno.2017.05.037_bb0015","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group","volume":"30","author":"Alsop","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2017.05.037_bb0020","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","article-title":"Meta-analysis of BRCA1 and BRCA2 penetrance","volume":"25","author":"Chen","year":"2007","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.05.037_bb0025","series-title":"Clinical Practice Guidelines in Oncology: Genetic\/Familial High-Risk Assessment: Breast and Ovarian [Internet]","author":"NCCN","year":"2008"},{"issue":"1","key":"10.1016\/j.ygyno.2017.05.037_bb0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2014.09.009","article-title":"Society of gynecologic oncology statement on risk assessment for inherited gynecologic cancer predispositions","volume":"136","author":"Lancaster","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2017.05.037_bb0035","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/gim.2014.147","article-title":"A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment","volume":"17","author":"Hampel","year":"2015","journal-title":"Genet. Med."},{"issue":"8","key":"10.1016\/j.ygyno.2017.05.037_bb0040","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1200\/JCO.2013.50.9257","article-title":"American society of clinical oncology expert statement: collection and use of a cancer family history for oncology providers","volume":"32","author":"Lu","year":"2014","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2017.05.037_bb0045","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ygyno.2015.04.029","article-title":"Adherence patterns to National Comprehensive Cancer Network (NCCN) guidelines for referral to cancer genetic professionals","volume":"138","author":"Febbraro","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2017.05.037_bb0050","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/IGC.0b013e318280f2b4","article-title":"Does the diagnosis of breast or ovarian cancer trigger referral to genetic counseling?","volume":"23","author":"Powell","year":"2013","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2017.05.037_bb0055","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.ajog.2016.02.011","article-title":"Underuse of BRCA testing in patients with breast and ovarian cancer","volume":"214","author":"Wright","year":"2016","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"1","key":"10.1016\/j.ygyno.2017.05.037_bb0060","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10549-015-3374-7","article-title":"Factors associated with genetic counseling and BRCA testing in a population-based sample of young black women with breast cancer","volume":"151","author":"Cragun","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"issue":"22","key":"10.1016\/j.ygyno.2017.05.037_bb0065","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1200\/JCO.2015.66.0019","article-title":"Health care segregation, physician recommendation, and racial disparities in BRCA1\/2 testing among women with breast cancer","volume":"34","author":"McCarthy","year":"2016","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2017.05.037_bb0070","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10897-013-9664-5","article-title":"The value of a genetic counselor: improving identification of cancer genetic counseling patients with chart review","volume":"23","author":"Eichmeyer","year":"2014","journal-title":"J. Genet. Couns."},{"issue":"5","key":"10.1016\/j.ygyno.2017.05.037_bb0075","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1001\/jama.2016.16918","article-title":"Genetic testing and counseling among patients with newly diagnosed breast cancer","volume":"317","author":"Kurian","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2017.05.037_bb0080","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/AOG.0b013e3181da08d7","article-title":"Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations","volume":"115","author":"Meyer","year":"2010","journal-title":"Obstet. Gynecol."},{"issue":"2","key":"10.1016\/j.ygyno.2017.05.037_bb0085","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J. Biomed. Inform."},{"key":"10.1016\/j.ygyno.2017.05.037_bb0090","series-title":"Plan-Do-Study-Act (PDSA) Cycle AHRQ","author":"Associates in Process Improvement","year":"2008"},{"issue":"19","key":"10.1016\/j.ygyno.2017.05.037_bb0095","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1158\/1078-0432.CCR-15-0887","article-title":"FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy","volume":"21","author":"Kim","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.ygyno.2017.05.037_bb0100","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-014-0442-6","article-title":"The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services","volume":"16","author":"Evans","year":"2014","journal-title":"Breast Cancer Res."},{"issue":"4","key":"10.1016\/j.ygyno.2017.05.037_bb0105","first-page":"597","article-title":"Myriad after myriad: the proprietary data dilemma","volume":"15","author":"Conley","year":"2014","journal-title":"N. C. J. Law Technol."},{"issue":"4","key":"10.1016\/j.ygyno.2017.05.037_bb0110","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1200\/JCO.2008.21.4684","article-title":"Preventing future cancers by testing women with ovarian cancer for BRCA mutations","volume":"28","author":"Kwon","year":"2010","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817308934?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817308934?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T15:55:46Z","timestamp":1656172546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825817308934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0090825817308934"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.05.037","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.05.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}